Phase II trial of combination therapy of gemcitabine plus anti-angiogenic vaccination of elpamotide in patients with advanced or recurrent biliary tract cancer

Background Elpamotide is an HLA-A*24:02-restricted epitope peptide of vascular endothelial growth factor receptor 2 (VEGFR-2) and induces cytotoxic T lymphocytes (CTLs) against VEGFR-2/KDR. Given the high expression of VEGFR-2 in biliary tract cancer, combination chemoimmunotherapy with elpamotide a...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuyama, Masato, Ishii, H., Furuse, J., Ohkawa, S., Maguchi, H., Mizuno, N., Yamaguchi, T., Ioka, T., Ajiki, T., Ikeda, M., Hakamada, K., Yamamoto, M., Yamaue, H., Eguchi, K., Ichikawa, W., Miyazaki, M., Ohashi, Y., Sasaki, Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2014
Materias:
Phase II Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4387249/
https://www.ncbi.nlm.nih.gov/pubmed/25502982
http://dx.doi.org/10.1007/s10637-014-0197-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4387249/
https://www.ncbi.nlm.nih.gov/pubmed/25502982
http://dx.doi.org/10.1007/s10637-014-0197-z

Ejemplares similares